Birtamimab Safety Profile in the VITAL Study

Opinion
Video

Dr. Zonder discusses the safety profile of birtamimab in the VITAL study and the clinical implications.

Related Videos
Video  10 -"Real-World Evidence on Second-Line Therapy Selection and Outcomes"
Video  9 - "Additional Second-Line Treatments for HCC"
A panel of 4 experts on colorectal cancer
Video 8 - "The Evolving Landscape of Second-Line Therapies in HCC Management"
Video 7 - "Comorbidity Considerations for HCC Treatment"
Related Content